erlotinib hydrochloride has been researched along with uridine in 1 studies
| Studies (erlotinib hydrochloride) | Trials (erlotinib hydrochloride) | Recent Studies (post-2010) (erlotinib hydrochloride) | Studies (uridine) | Trials (uridine) | Recent Studies (post-2010) (uridine) |
|---|---|---|---|---|---|
| 4,353 | 786 | 3,033 | 12,749 | 69 | 1,083 |
| Protein | Taxonomy | erlotinib hydrochloride (IC50) | uridine (IC50) |
|---|---|---|---|
| Sodium/nucleoside cotransporter 1 | Homo sapiens (human) | 5.8 | |
| Solute carrier family 28 member 3 | Homo sapiens (human) | 5.4 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cass, CE; Damaraju, VL; Kuzma, M; Mowles, D; Ryan, AJ; Sawyer, MB; Scriver, T | 1 |
1 other study(ies) available for erlotinib hydrochloride and uridine
| Article | Year |
|---|---|
Erlotinib, gefitinib, and vandetanib inhibit human nucleoside transporters and protect cancer cells from gemcitabine cytotoxicity.
Topics: Antimetabolites, Antineoplastic; Biological Transport; Cell Line, Tumor; Cell Survival; Deoxycytidine; Drug Screening Assays, Antitumor; Drug Synergism; Erlotinib Hydrochloride; Gefitinib; Gemcitabine; Humans; Inhibitory Concentration 50; Nucleoside Transport Proteins; Piperidines; Quinazolines; Saccharomyces cerevisiae; Uridine | 2014 |